Dear editor,

Coronavirus disease 2019 (COVID- 19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an unprecedented global public health crisis. Worldwide, around 4 million infected cases and around 278,000 related-deaths have been reported by May 10, 2020. Mounting evidence has suggested that critical cases are due to development of acute respiratory distress syndrome (ARDS) and subsequent respiratory failure, owing to what is called a cytokine storm syndrome (CSS). As the name implies, the CSS is characterised by a sudden, abnormal release of inflammatory cytokines including many interlukins (IL) like IL-1β, IL-12, IL-6, IL-18, and IL-33, interferon α and γ (IFN- α and γ), tumor necrosis factor α (TNF-α), and tumor growth factor β (TGFβ), due to over-reaction of the innate immunity [@b0005]. Additionally CSS has been shown to induce many reactive oxygen species [@b0010]. As mentioned earlier, CSS is strongly associated with severe tissue damage, contributing to the fatal outcomes of COVID-19 [@b0005].

Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid. It is the therapeutically active component of bear bile, and has been used in traditional Chinese medicine for more than 3000 years. Normally, UDCA present in human bile but in a low concentration: 3% of bile acid pool. It has been shown to possess anti-inflammatory, antioxidant, immunomodulatory and anti-apoptotic properties [@b0015], [@b0020]. In many studies, UDCA inhibits the pro-inflammatory cytokines of TNF-α, IL-1β, IL-2, IL-4 and IL-6 at the mRNA and protein levels [@b0025], [@b0030]. Additionally, study showed that UDCA has strong antioxidant properties and remarkable scavenging efficiency [@b0035] Drug-induced liver injury has become a serious health problem, UDCA, with its known liver-protection effects, may play an auxiliary role in COVID-19 treatment. UDCA, at a dose of 13-15mg/kg/day, is a safe and recommended.

UDCA has been approved by the US Food and Drug Administration (FDA) for dissolving gall stone, and for treatment of several cholestatic liver diseases such as primary biliary cholangitis [@b0040]. The beneficial action of UDCA in respiratory diseases has been previously demonstrated; it showed a significant improvement in all histopathological changes that occurred in context of airway remodeling. These beneficial effects might be ascribed to the efficient modulation of Th-2 derived cytokines and the inhibition of apoptosis of airway epithelial cells [@b0045]. Recently, UDCA has been shown to stimulate alveolar fluid clearance in lipopolysaccharide-induced pulmonary edema via ALX/cAMP/PI3K pathway resulting in an improvement of acute respiratory distress syndrome [@b0050]. The latter study clearly indicates that UDCA may have promising therapeutic effects in COVID-19- induced pneumonia and related lung oedema.

Given its anti-inflammatory and immune modulating actions, we suggest adding UDCA to the current treatment protocols of COVID-19 as it might be effective in tackling CSS due to its ability to suppress the immune mediators. This hypothesis merits clinical trials.
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